Peter W. Hennessey


In 2012, Novocure, an oncology company, introduced its Optune® device, which uses electrical fields (Tumor Treating Fields) to disrupt cell division and fight cancer. Optune® is FDA approved for treatment of the most aggressive form of brain cancer and glioblastoma, and Novocure is conducting clinical trials on a variety of other cancers.

Starting in 2013, Spark Therapeutics, a Philadelphia-based startup pharmaceutical company, has been working to commercially develop treatments against hemophilia. Life Sciences and Technology Partner Peter Hennessey will moderate a discussion between Spark Chief Legal Officer Joseph La Barge and Novocure Deputy General Counsel Kimberly Burke on the challenges of bringing a groundbreaking technology to market.

Click here for more information or to register.

Related Practice

Life Sciences and Technology